Page last updated: 2024-10-24

bupivacaine and Esophageal Reflux

bupivacaine has been researched along with Esophageal Reflux in 3 studies

Bupivacaine: A widely used local anesthetic agent.
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.
bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Allen, MS	1
Halgren, L	1
Nichols, FC	1
Cassivi, SD	1
Harmsen, WS	1
Wigle, DA	1
Shen, KR	1
Deschamps, C	1
Weinstabl, C	1
Porges, P	1
Plainer, B	1
Werba, A	1
Spiss, CK	1
Seitz, H	1
Eng, J	1
Sabanathan, S	1

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Controlled Trial of the Effectiveness of Liposomal Bupivacaine (Exparel) When Compared to Local Injection of Bupivacaine After Thoracoscopy[NCT02499159]	Phase 4	100 participants (Actual)	Interventional	2014-12-31	Completed
A Randomized Controlled Trial of Continuous Subpleural Infusion of Bupivacaine After Thoracoscopy[NCT01566838]		83 participants (Actual)	Interventional	2012-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Days Until Return to Work

Using surveys, the number of days to return to work was assessed for patients who were able to return to work. (NCT02499159)
Timeframe: Assessed at 30 days post-procedure

Intervention	days (Median)
Exparel	6.5
0.25% Standard Bupivicaine	5

Hospital Length of Stay

Median length of stay in days until discharge. (NCT02499159)
Timeframe: From end of procedure until discharge, usually 0-2 days.

Intervention	days (Median)
Exparel	0
0.25% Standard Bupivicaine	0

Number of Patients With Paresthesias (Postoperatively at 7 Days)

Patients are asked if they have experienced a pricking or tingling sensation caused by potential pressure or damage to peripheral nerves since the procedure. (NCT02499159)
Timeframe: Assessed at day 7 post-procedure

Intervention	Participants (Count of Participants)
Exparel	10
0.25% Standard Bupivicaine	20

Overall Amounts of Pain Medications Consumed Through Post-operative Day 7

Using questionnaires, patients are asked if they took Dilaudid, Tylenol, Motrin, or other opioids and if so, how many tablets. (NCT02499159)
Timeframe: Assessed daily for 7 days post-procedure

Intervention	tablets (Number)
Exparel	1294
0.25% Standard Bupivicaine	1455.5

Proportion of Patients With Paresthesias (Postoperatively at 30 Days)

Patients are asked if they have experienced a pricking or tingling sensation caused by potential pressure or damage to peripheral nerves (NCT02499159)
Timeframe: Assessed at day 30 post-procedure

Intervention	Participants (Count of Participants)
Exparel	6
0.25% Standard Bupivicaine	5

Return to Baseline Activity

Using surveys, patients are asked if they have been able to return to baseline activity levels. (NCT02499159)
Timeframe: Assessed at 30 days post-procedure

Intervention	Participants (Count of Participants)
Exparel	40
0.25% Standard Bupivicaine	47

Return to Work

Using surveys, patients are asked if they have been able to return to work. (NCT02499159)
Timeframe: Assessed at 30 days post-procedure

Intervention	Participants (Count of Participants)
Exparel	24
0.25% Standard Bupivicaine	17

Scores on a Analog Pain Scale (7 Days)

Using questionnaires, patients are asked what their pain level is based on a scale from 0-10, 10 being the absolute worst pain and 0 being no pain. (NCT02499159)
Timeframe: Assessed at day 7 post-procedure

Intervention	Median score on postoperative day 7 (Median)
Exparel	1.5
0.25% Standard Bupivicaine	1

Scores on an Analog Pain Scale (30 Days)

Intervention	Median score on postoperative day 30 (Median)
Exparel	0
0.25% Standard Bupivicaine	0

Length of Stay

Hospital length of stay for this operation will be recorded and analyzed for each arm of the study. (NCT01566838)
Timeframe: Participants will be followed for the duration of hospital stay, an expected average of 5 days

Intervention	days (Median)
On-q Pump	1
Standard of Care	1

30-day Incidence of Parasthesia

30-day incidence of paresthesia (tingling or pricking sensation, usually caused by pressure or nerve damage) (NCT01566838)
Timeframe: 30 days

Intervention	participants (Number)
	Yes	No
On-q Pump	13	25
Standard of Care	15	27

7-day Paresthesia

Participants experiencing parasthesia (a tingling or pricking sensation usually caused by pressure or damage to nerves) through postoperative day 7 (NCT01566838)
Timeframe: Postoperative day 1 through day 7

Intervention	participants (Number)
	Yes	No	Unknown
On-q Pump	3	25	10
Standard of Care	1	25	16

Number of Participants With and Without 30-Day Pain Medication Usage

The primary outcome will measure narcotics usage from post-operative day 1 through post-operative day 30. (NCT01566838)
Timeframe: Postoperative day 1 through postoperative day 30

Intervention	participants (Number)
	Yes	No
On-q Pump	8	30
Standard of Care	6	36

Resumed Physical Activity

Did the patient resume physical activity. (NCT01566838)
Timeframe: 30 days

Intervention	participants (Number)
	Yes	No
On-q Pump	37	1
Standard of Care	37	5

Return to Work

Returned to work in 30 days? (NCT01566838)
Timeframe: 30 days

Intervention	participants (Number)
	Yes	No	Not currently working
On-q Pump	18	3	17
Standard of Care	20	3	19

Trials

1 trial available for bupivacaine and Esophageal Reflux

Article	Year
A randomized controlled trial of bupivacaine through intracostal catheters for pain management after thoracotomy. The Annals of thoracic surgery, 2009, Volume: 88, Issue:3 Topics: Administration, Oral; Aged; Analgesia, Epidural; Analgesia, Patient-Controlled; Analgesics, Opioid;	2009
A randomized controlled trial of bupivacaine through intracostal catheters for pain management after thoracotomy. The Annals of thoracic surgery, 2009, Volume: 88, Issue:3 Topics: Administration, Oral; Aged; Analgesia, Epidural; Analgesia, Patient-Controlled; Analgesics, Opioid;	2009
A randomized controlled trial of bupivacaine through intracostal catheters for pain management after thoracotomy. The Annals of thoracic surgery, 2009, Volume: 88, Issue:3 Topics: Administration, Oral; Aged; Analgesia, Epidural; Analgesia, Patient-Controlled; Analgesics, Opioid;	2009
A randomized controlled trial of bupivacaine through intracostal catheters for pain management after thoracotomy. The Annals of thoracic surgery, 2009, Volume: 88, Issue:3 Topics: Administration, Oral; Aged; Analgesia, Epidural; Analgesia, Patient-Controlled; Analgesics, Opioid;	2009

Other Studies

2 other studies available for bupivacaine and Esophageal Reflux

Article	Year
Coeliac plexus block with bupivacaine reduces intestinal dysfunction in neurosurgical ICU patients. Anaesthesia, 1993, Volume: 48, Issue:2 Topics: Adult; Aged; Autonomic Nerve Block; Brain; Bupivacaine; Celiac Plexus; Craniocerebral Trauma; Female	1993
Continuous paravertebral block for postthoracotomy analgesia in children. Journal of pediatric surgery, 1992, Volume: 27, Issue:5 Topics: Adolescent; Analgesia; Bupivacaine; Catheterization, Peripheral; Child; Female; Gastroesophageal Ref	1992